{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:11Z","timestamp":1792047791675,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91959207 and 92159301"],"award-info":[{"award-number":["91959207 and 92159301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["21ZR1414700"],"award-info":[{"award-number":["21ZR1414700"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results of FUTURE, a phase II umbrella trial designed to explore whether the subtyping-based strategy may improve the outcomes in metastatic TNBC patients. A total of 141 patients with a median of three previous lines of therapies in the metastatic setting were enrolled in seven parallel arms. Confirmed objective responses were achieved in 42 patients (29.8%; 95% confidence interval [CI], 22.4\u201338.1). The median values of progression-free survival and overall survival were 3.4 (95% CI: 2.7\u20134.2) and 10.7 (95% CI: 9.1\u201312.3) months, respectively. Given Bayesian predictive probability, efficacy boundaries were achieved in four arms. Furthermore, integrated genomic and clinicopathological profiling illustrated associations of clinical and genomic parameters with treatment efficacy, and the efficacy of novel antibody\u2013drug conjugates was explored in preclinical TNBC models of subtypes for which treatment was futile. In general, the FUTURE strategy recruits patients efficiently and provides promising efficacy with manageable toxicities, outlining a direction for further clinical exploration.<\/jats:p>","DOI":"10.1038\/s41422-023-00795-2","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:03:12Z","timestamp":1679911392000},"page":"389-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial"],"prefix":"10.1038","volume":"33","author":[{"given":"Yin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Yong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Da","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-0505","authenticated-orcid":false,"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"795_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288\u2013300 (2019).","journal-title":"JAMA"},{"key":"795_CR2","doi-asserted-by":"crossref","unstructured":"Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1684\u20131735 (2018).","DOI":"10.1016\/S0140-6736(18)31891-9"},{"key":"795_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ajco.12748","volume":"14","author":"P Khosravi-Shahi","year":"2018","unstructured":"Khosravi-Shahi, P., Cabez\u00f3n-Guti\u00e9rrez, L. & Custodio-Cabello, S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac. J. Clin. Oncol. 14, 32\u201339 (2018).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"795_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"795_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"795_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"795_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"795_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30569-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat. Commun. 13, 3011 (2022).","journal-title":"Nat. Commun."},{"key":"795_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31, 1526\u20131535 (2020).","journal-title":"Ann. Oncol."},{"key":"795_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"795_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 499\u2013511 (2021).","journal-title":"Lancet Oncol."},{"key":"795_CR12","unstructured":"Ma, D. et al. Molecular features and functional implications of germline variants in triple-negative breast cancer. J. Natl. Cancer Inst. 113, 884\u2013892 (2021)."},{"key":"795_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"795_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner, N. C. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296\u20131308 (2020).","journal-title":"Lancet Oncol."},{"key":"795_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","volume":"583","author":"G Middleton","year":"2020","unstructured":"Middleton, G. et al. The national lung matrix trial of personalized therapy in lung cancer. Nature 583, 807\u2013812 (2020).","journal-title":"Nature"},{"key":"795_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: The VIKTORY umbrella trial. Cancer Discov. 9, 1388\u20131405 (2019).","journal-title":"Cancer Discov."},{"key":"795_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","volume":"25","author":"DG Rothwell","year":"2019","unstructured":"Rothwell, D. G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat. Med. 25, 738\u2013743 (2019).","journal-title":"Nat. Med."},{"key":"795_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35, 428\u2013440.e5 (2019).","journal-title":"Cancer Cell"},{"key":"795_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19342-3","volume":"11","author":"GT Lang","year":"2020","unstructured":"Lang, G. T. et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat. Commun. 11, 5679 (2020).","journal-title":"Nat. Commun."},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"795_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21, 1688\u20131698 (2015).","journal-title":"Clin. Cancer Res."},{"key":"795_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11427-020-1714-8","volume":"64","author":"SY Wu","year":"2021","unstructured":"Wu, S. Y., Wang, H., Shao, Z. M. & Jiang, Y. Z. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci. China Life Sci. 64, 372\u2013388 (2021).","journal-title":"Sci. China Life Sci."},{"key":"795_CR23","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","volume":"25","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 25, e1481\u2013e1491 (2020).","journal-title":"Oncologist"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 31, 178\u2013186 (2021).","journal-title":"Cell Res."},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrclinonc.2011.165","volume":"9","author":"DA Berry","year":"2011","unstructured":"Berry, D. A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199\u2013207 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"795_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 351\u2013360 (2021).","journal-title":"Lancet Oncol."},{"key":"795_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. 72, 165\u2013182 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"795_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"795_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"SY Wu","year":"2022","unstructured":"Wu, S. Y. et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol. Cancer 21, 84 (2022).","journal-title":"Mol. Cancer"},{"key":"795_CR30","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial. Clin. Cancer Res. 28, 2807\u20132817 (2022).","DOI":"10.1158\/1078-0432.CCR-21-4313"},{"key":"795_CR31","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ijc.28829","volume":"135","author":"X Hu","year":"2014","unstructured":"Hu, X. et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int. J. Cancer 135, 1961\u20131969 (2014).","journal-title":"Int. J. Cancer"},{"key":"795_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224\u2013237 (2013).","journal-title":"Cancer Discov."},{"key":"795_CR33","doi-asserted-by":"publisher","first-page":"GS4-10","DOI":"10.1158\/1538-7445.SABCS21-GS4-10","volume":"82\u00a0(4_Supplemen","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri, K. et al. Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. Cancer Res. 82\u00a0(4_Supplement), GS4-10 (2022).","journal-title":"Cancer Res."},{"key":"795_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. J. Clin. Oncol. 38, 423\u2013433 (2020).","journal-title":"J. Clin. Oncol."},{"key":"795_CR35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","volume":"18","author":"SB Kim","year":"2017","unstructured":"Kim, S. B. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 18, 1360\u20131372 (2017).","journal-title":"Lancet Oncol."},{"key":"795_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12254-021-00722-4","volume":"14","author":"R Bartsch","year":"2021","unstructured":"Bartsch, R. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. Memo 14, 247\u2013251 (2021).","journal-title":"Memo"},{"key":"795_CR37","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia, A. et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 35, 2141\u20132148 (2017).","journal-title":"J. Clin. Oncol."},{"key":"795_CR38","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32, 1148\u20131156 (2021).","journal-title":"Ann. Oncol."},{"key":"795_CR39","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar, U. S. et al. Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer. Clin. Cancer Res. 23, 5561\u20135572 (2017).","journal-title":"Clin. Cancer Res."},{"key":"795_CR40","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","volume":"19","author":"A Gucalp","year":"2013","unstructured":"Gucalp, A. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin. Cancer Res. 19, 5505\u20135512 (2013).","journal-title":"Clin. Cancer Res."},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdw067","volume":"27","author":"H Bonnefoi","year":"2016","unstructured":"Bonnefoi, H. et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann. Oncol. 27, 812\u2013818 (2016).","journal-title":"Ann. Oncol."},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377, 914\u2013923 (2011).","journal-title":"Lancet"},{"key":"795_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1740774508089279","volume":"5","author":"JJ Lee","year":"2008","unstructured":"Lee, J. J. & Liu, D. D. A predictive probability design for phase II cancer clinical trials. Clin. Trials 5, 93\u2013106 (2008).","journal-title":"Clin. Trials"},{"key":"795_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur. J. Cancer 62, 138\u2013145 (2016).","journal-title":"Eur. J. Cancer"},{"key":"795_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","volume":"173","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 173, 305\u2013320.e10 (2018).","journal-title":"Cell"},{"key":"795_CR46","doi-asserted-by":"crossref","unstructured":"Gong, Y. et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 33, 51\u201364.e9 (2021).","DOI":"10.1016\/j.cmet.2020.10.012"},{"key":"795_CR47","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/jnci\/dji400","volume":"97","author":"JS Lewis","year":"2005","unstructured":"Lewis, J. S. et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl Cancer Inst. 97, 1746\u20131759 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"795_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","volume":"40","author":"X Zhu","year":"2021","unstructured":"Zhu, X. et al. Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer. J. Exp. Clin. Cancer Res. 40, 122 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"795_CR49","doi-asserted-by":"crossref","unstructured":"Xiao, Y. et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 32, 477\u2013490 (2022).","DOI":"10.1038\/s41422-022-00614-0"},{"key":"795_CR50","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub, A. N. et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res. 21, 3870\u20133878 (2015).","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41422-023-00795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-023-00795-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-023-00795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:03:18Z","timestamp":1683111798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41422-023-00795-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1038\/s41422-023-00795-2","relation":{},"ISSN":["1748-7838"],"issn-type":[{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.-Y.Z. is an employee of Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine). All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}